Patrick F. Belcastro, PhD is a Pharmtech editorial advisory board (EAB) member.
Patrick F. Belcastro, PhD
Professor Emeritus,
School of Pharmacy,
Purdue University
Patrick F. Belcastro is professor emeritus of pharmaceutics in the department of industrial and physical pharmacy at Purdue University. He received an MS and PhD degree from Purdue University’s School of Pharmacy and Pharmaceutical Sciences.
His published articles, appearing in various professional and scientific periodicals, cover a wide variety of subject areas, including studies on the effects of x-radiation on the intestinal absorption and thyroid uptake of radioactive iodine-131, the effect of ultrasonic energy on the particle size of suspended pharmaceuticals, and other areas. Belcastro has served as a member of the editorial advisory board of Pharmaceutical Technology since 1977. He is a member of the American Pharmaceutical Association and the American Institute of the History of Pharmacy.
Over the years, Belcastro has taught a wide variety of graduate and undergraduate courses including those involving the manufacture and compounding of parenteral solutions. He has directed graduate studies of doctoral students at Purdue University, where he currently teaches an elective undergraduate course. He has also served as a member of the faculty at Duquesne University and at Ohio State University.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.